← 返回

异基因 NK 细胞联合髓系细胞治疗急性髓系白血病机制研究

英文原题:Study on the Mechanisms of Allogeneic NK Cells Combined with Myeloid Cells in Treating Acute Myeloid Leukemia.

查看英文原题

Study on the Mechanisms of Allogeneic NK Cells Combined with Myeloid Cells in Treating Acute Myeloid Leukemia.

PubMed 2026/04/24(内容时间) Transplant Cell Ther Q1 · IF 4.7(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

中文摘要

异基因造血干细胞微移植(MST)在先前的研究中已显示,与单纯化疗相比,可改善急性髓系白血病的结局,但其机制需要进一步研究。在MST中,供者经粒细胞集落刺激因子(G-CSF)动员的外周血单个核细胞(GPBMCs)含有大量NK细胞,在每个化疗周期后输注(通常总共3至5次输注)。

本研究旨在探讨G-CSF动员的NK细胞是否发挥抗肿瘤作用及其涉及的潜在机制。比较了G-CSF动员前后NK细胞的表型、细胞毒性和细胞因子产生。对72例接受MST治疗的AML患者进行了回顾性分析。研究了NK细胞剂量和KIR配体错配对生存的影响。分离了8名供者G-CSF动员前后的NK细胞,以评估表型、杀伤活性和细胞因子产生。通过单细胞RNA测序(scRNA-seq)分析基因表达和细胞间通讯。在单变量分析中,较高的NK细胞剂量与生存改善相关;然而,在多变量调整后,这种关联未保持统计学显著性,而KIR配体错配和供者活化受体数量则不是。G-CSF动员增加了CD56 bright NK细胞的比例,并上调了抑制性受体TIGIT,同时下调了NKG2D。

动员后的NK细胞对K562细胞的细胞毒性降低,穿孔素和颗粒酶B释放减少,IFN-产生减少。scRNA-seq显示,动员后的NK细胞上调了与免疫调节、髓系细胞相互作用和趋化因子信号传导相关的基因。配体-受体配对分析提示,动员后与髓系细胞的潜在相互作用增强,尤其是涉及 C5AR1 和 CCL5 通路。G-CSF 动员会改变 NK 细胞的表型并降低其直接细胞毒功能,同时富集具有免疫调节基因表达谱的亚群。这些发现提出了如下假设:动员后的 NK 细胞可能通过与髓系细胞的 crosstalk 间接支持抗肿瘤免疫。仍需进一步研究以在体内验证这些相互作用及其功能后果。

展开英文摘要原文

Allogeneic hematopoietic stem cell microtransplantation (MST) has been shown in prior studies to improve outcomes compared to chemotherapy alone in acute myeloid leukemia, but its mechanism requires further investigation. In MST, donor peripheral blood mononuclear cells (GPBMCs) mobilized by granulocyte colony-stimulating factor (G-CSF), which contain a large number of NK cells, are infused after each chemotherapy cycle (typically 3 to 5 infusions total).

This study was designed to investigate whether G-CSF-mobilized NK cells exert antitumor effects and the underlying mechanisms involved. NK cell phenotype, cytotoxicity, and cytokine production were compared before and after G-CSF mobilization. Seventy-two AML patients treated with MST were retrospectively analyzed. The effects of NK cell dose and KIR ligand mismatch on survival were studied. NK cells from 8 donors were isolated before and after G-CSF mobilization to assess phenotype, killing activity, and cytokine production. Gene expression and cell-cell communication were analyzed via single-cell RNA sequencing (scRNA-seq). In univariable analysis, higher NK cell doses were associated with improved survival; however, this association did not retain statistical significance after multivariable adjustment, whereas KIR ligand mismatch and donor activating receptor numbers were not.

G-CSF mobilization increased the proportion of CD56 bright NK cells and upregulated the inhibitory receptor TIGIT, while downregulating NKG2D. Mobilized NK cells showed reduced cytotoxicity against K562 cells, lower perforin and granzyme B release, and decreased IFN- production. scRNA-seq revealed that mobilized NK cells upregulated genes associated with immune regulation, myeloid cell interaction, and chemokine signaling.

Ligand-receptor pairing analysis suggested enhanced potential interactions with myeloid cells post-mobilization, particularly involving C5AR1 and CCL5 pathways. G-CSF mobilization alters the phenotype and reduces the direct cytotoxic function of NK cells, while enriching for subsets with immunomodulatory gene expression profiles.

These findings generate hypotheses that mobilized NK cells may support antitumor immunity indirectly through crosstalk with myeloid cells.

Further studies are needed to validate these interactions and their functional consequences in vivo.

论文信息

作者
Zhang TY、Liu RY、Lei YY、Cai B、Yu CL、Guo M、Ai HS、Wang Y
第一作者单位
Department of Hematology, The PLA 307 Clinical College of Anhui Medical University, The Fifth Clinical Medical College of Anhui Medical University, Hefei, Anhui, China.China
通讯作者单位
Department of Hematology and Transplantation, The Fifth Medical Center, General Hospital of the People's Liberation Army, Beijing, China; Department of Hematology, The PLA 307 Clinical College of Anhui Medical University, The Fifth Clinical Medical College of Anhui Medical University, Hefei, Anhui, China. Electronic address: hukaixun307@163.com.China
期刊
Transplantation and cellular therapy2026 Aug
原文标识
PubMed 42035877 · DOI 10.1016/j.jtct.2026.03.043